Hepatitis A vaccine inactivated - Merck

Drug Profile

Hepatitis A vaccine inactivated - Merck

Alternative Names: Vaqta

Latest Information Update: 12 Jan 2017

Price : $50

At a glance

  • Originator Merck & Co
  • Class Hepatitis A vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis A

Most Recent Events

  • 02 Jan 2017 Sanofi Pasteur MSD ended their joint venture and will separately pursue their vaccine strategies in Europe
  • 23 Nov 2006 SBL Vaccin AB has been acquired by Crucell
  • 18 Aug 2005 Registered for hepatitis A in children aged 12 months and older
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top